Drugs for Functioning Pituitary Adenoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show top 50)
(show all 87)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Metformin |
Approved |
Phase 4 |
|
1115-70-4, 657-24-9 |
4091 |
Synonyms:
[<sup>14</sup>C]-metformin
1,1-Dimethyl biguanide
1,1-Dimethylbiguanide
1-CARBAMIMIDAMIDO-N,N-DIMETHYLMETHANIMIDAMIDE
Apo-Metformin
BOLAMYN SR
Diabefagos
Diabex
Diaformin
DIAGEMET XL
Dianben
Dimethylbiguanid
Dimethylbiguanide
Dimethylbiguanidine
Dimethyldiguanide
Dimethylguanylguanidine
DMBG
Fortamet
Gen-Metformin
GLUCAMET 500
GLUCAMET 850
GLUCIENT SR
Glucophage
GLUCOPHAGE SR
GLUCOPHAGE XR
Glumetza
Glycon
GLYFORMIN
HCL, Metformin
Hydrochloride, metformin
JANUMET
LA 6023
LA-6023
|
LEDERMETIN
Meguan
METABET SR
Metformin
Metformin HCL
Metformin hydrochloride
Metformina
Metformine
Metforminum
Metiguanide
METSOL
MILFORM
Mylan-Metformin
N(1),N(1)-Dimethylbiguanide
N,N-Dimethylbiguanide
N,N-Dimethyldiguanide
N,N-Dimethylguanylguanidine
N,N-Dimethylimidodicarbonimidic diamide
N1,N1-Dimethylbiguanide
Novo-Metformin
NSC-91485
Nu-Metformin
Obimet
ORABET
PMS-Metformin
Ran-Metformin
Ratio-Metformin
Riomet
Sandoz Metformin
SUKKARTO SR
Teva-Metformin
XLA399
|
|
2 |
|
Liraglutide |
Approved |
Phase 4 |
|
204656-20-2 |
44147092 16134956 |
Synonyms:
ARG34LYS26-(N-Ε-(Γ-GLU(N-Α-HEXADECANOYL)))-GLP-1[7-37]
LIRAGLUTIDA
LIRAGLUTIDE
Liraglutide (genetical recombination)
Liraglutide (rDNA origin)
LIRAGLUTIDE RECOMBINANT
LIRAGLUTIDUM
N²⁶-(HEXADECANOYL-GAMMA-GLUTAMYLE)-[34-ARGININE]GLP-1-(7-37)-PEPTIDE
N²⁶-(N-HEXADECANOYL-L-GAMMA-GLUTAMYL)-[34-L-ARGININE]GLUCAGON-LIKE PEPTIDE 1-(7-37)-PEPTIDE
NN 2211
|
NN2211
NN-2211
NN-2211|NN2211|Victoza®
NN9924
NN-9924
NNC 90-1170
NNC-90-1170
SAXENDA
VICTOZA
|
|
3 |
|
Pasireotide |
Approved |
Phase 4 |
|
396091-73-9 |
56841596 9941444 |
Synonyms:
cyclo((4R)-4-(2-aminoethylcarbamoyloxy)-L-prolyl-L-phenylglycyl-D-tryptophyl-L-lysyl-4-O-benzyl-L-tyrosyl-L- phenylalanyl-)
Pasireotida
Pasireotide
Pasiréotide
pasireotide diaspartate|Signifor®|SOM 230|SOM 320|SOM-230
|
Pasireotidum
SIGNIFOR
SOM 230
SOM230
SOM-230
|
|
4 |
|
Somatostatin |
Approved, Investigational |
Phase 4 |
|
38916-34-6, 51110-01-1 |
53481605 16129706 |
Synonyms:
(5S,8R,14R,17R,20R,23R,26R,29R,32R,35R)-38-[(2-{[(2R)-2-amino-1-hydroxypropylidene]amino}-1-hydroxyethylidene)amino]-20,35-bis(4-aminobutyl)-14,26,29-tribenzyl-7,10,13,16,19,22,25,28,31,34,37-undecahydroxy-32-[(C-hydroxycarbonimidoyl)methyl]-11-(1-hydroxyethyl)-17-[(1S)-1-hydroxyethyl]-8-(hydroxymethyl)-23-[(1H-indol-3-yl)methyl]-1,2-dithia-6,9,12,15,18,21,24,27,30,33,36-undecaazacyclononatriaconta-6,9,12,15,18,21,24,27,30,33,36-undecaene-5-carboxylate
ALA-GLY-CYCLO-[CYS-LYS-ASN-PHE-PHE-TRP-LYS-THR-PHE-THR-SER-CYS]
Growth hormone-inhibiting hormone (ghih)
L-ALANYLGLYCYL-L-CYSTEINYL-L-LYSYL-L-ASPARAGINYL-L-PHENYLALANYL-L-PHENYLALANYL-L-TRYPTOPHYL-L-LYSYL-L-THREONYL-L-PHENYLALANYL-L-THREONYL-L-SERYL-L-CYSTEINE CYCLIC (3-14) DISULFIDE
SOMATOSTATIN
SOMATOSTATIN-1
SOMATOSTATIN-14
SOMATOSTATINA
|
SOMATOSTATINE
SOMATOSTATINUM
Somatotropin release-inhibiting factor (srif)
Somatotropin release-inhibiting hormone
SRIF-14
SYNTHETIC GROWTH HORMONE RELEASE-INHIBITING HORMONE
SYNTHETIC SOMATOSTATIN-14
|
|
5 |
|
Cabergoline |
Approved |
Phase 4 |
|
81409-90-7 |
54746 |
Synonyms:
(8b)-N-[3-(Dimethylamino)propyl]-N-[(ethylamino)carbonyl]-6-(2-propenyl)-ergoline-8-carboxamide
(8beta)-N-[3-(Dimethylamino)propyl]-N-[(ethylamino)carbonyl]-6-(2-propenyl)-ergoline-8-carboxamide
(8R)-6-Allyl-N-[3-(dimethylamino)propyl]-N-(ethylcarbamoyl)ergoline-8-carboxamide
(8Β)-N-[3-(dimethylamino)propyl]-N-[(ethylamino)carbonyl]-6-(2-propenyl)-ergoline-8-carboxamide
1-((6-Allylergolin-8beta-yl)carbonyl)-1-(3-(dimethylamino)propyl)-3-ethylurea
1-((6-Allylergolin-8b-yl)carbonyl)-1-(3-(dimethylamino)propyl)-3-ethylurea
1-((6-Allylergolin-8β-yl)carbonyl)-1-(3-(dimethylamino)propyl)-3-ethylurea
1-[(6-Allylergoline-8beta-yl)carbonyl]-1-[3-(dimethylamino)propyl]-3-ethylurea
1-[(6-Allylergoline-8b-yl)carbonyl]-1-[3-(dimethylamino)propyl]-3-ethylurea
1-[(6-Allylergoline-8β-yl)carbonyl]-1-[3-(dimethylamino)propyl]-3-ethylurea
1-Ethyl-2-(3'-dimethylaminopropyl)-3-(6'-allylergoline-8'-beta-carbonyl)urea diphosphate
1-Ethyl-3-(3'-dimethylamionpropyl)-2-(6'-allylergoline-8'b-carbonyl)urea
1-Ethyl-3-(3'-dimethylamionpropyl)-2-(6'-allylergoline-8'beta-carbonyl)urea
|
1-Ethyl-3-(3'-dimethylamionpropyl)-2-(6'-allylergoline-8'β-carbonyl)urea
Cabaser
Cabaser®|Caberlin®
Cabaseril
Cabergolina
Cabergoline
Cabergoline diphosphate
Cabergolinum
CABERLIN
Dostinex
FCE-21336
Galastop
|
|
6 |
|
Dopamine |
Approved |
Phase 4 |
|
62-31-7, 51-61-6 |
681 |
Synonyms:
2-(3,4-Dihydroxyphenyl)ethylamine
3,4 Dihydroxyphenethylamine
3,4-Dihydroxyphenethylamine
3,4-Dihydroxyphenylethylamine
3-Hydroxytyramine
4-(2-Aminoethyl)-1,2-benzenediol
4-(2-Aminoethyl)benzene-1,2-diol
4-(2-Aminoethyl)catechol
4-(2-Aminoethyl)pyrocatechol
4-(2-Aminoethyl)-pyrocatechol
4-(2-AZANYLETHYL)BENZENE-1,2-DIOL
a-(3,4-Dihydroxyphenyl)-b-aminoethane
alpha-(3,4-Dihydroxyphenyl)-beta-aminoethane
ASL-279
CARBILEV
Deoxyepinephrine
Dopamin
Dopamina
DOPAMINE
DOPAMINE HCL
|
Dopamine hydrochloride
DOPAMIN-NATTERMAN
Dopaminum
Dopastat
Dophamine
DOPMIN
Dynatra
Hydrochloride, dopamine
Hydroxytyramin
Hydroxytyramine
Intropin
Medopa
NSC-169105
NSC-173182
Oxytyramine
PARCOPA
Revivan
SABAX DOPAMIN
SELECTAJET
SINEMET
|
|
7 |
|
Lactitol |
Approved, Investigational |
Phase 4 |
|
585-86-4 |
157355 |
Synonyms:
4-O-beta-D-Galactopyranosyl-D-glucitol
4-O-β-D-Galactopyranosyl-D-glucitol
D-Lactitol
Emportal
Importal
Lactitol
|
Lactitolum
Neda lactiv importal
Oponaf
Pizensy
WURCS=2.0/2,2,1/[H2122H][a2112h-1b_1-5]/1-2/a4-b1
|
|
8 |
|
HIV Protease Inhibitors |
|
Phase 4 |
|
|
|
9 |
|
protease inhibitors |
|
Phase 4 |
|
|
|
Synonyms:
|
10 |
|
Insulin, Globin Zinc |
|
Phase 4 |
|
|
|
11 |
|
Insulin |
|
Phase 4 |
|
|
|
Synonyms:
AFREZZA
EXUBERA
HUMULIN
HUMULIN BR
HUMULIN R
HUMULIN R KWIKPEN
HUMULIN R PEN
INS HUMULIN R
INSULIN
INSULIN (HUMAN)
INSULIN BOVINE
INSULIN BOVINE INSULIN
|
INSULIN HUMAN
INSULIN HUMAN (BIOSYNTHESIS)
INSULIN HUMAN (SYNTHESIS)
INSULIN RECOMBINANT HUMAN
INSULIN RECOMBINANT PURIFIED HUMAN
INSUMAN INFUSAT
MYXREDLIN
NOVOLIN
NOVOLIN R
VELOSULIN
VELOSULIN BR
VELOSULIN BR HUMAN
|
|
12 |
|
Sitagliptin Phosphate |
|
Phase 4 |
|
654671-77-9 |
|
Synonyms:
JANUMET XR
JANUVIA
MK0431
MK-0431
ONO-5435
|
SITAGLIPTIN MONOPHOSPHATE ANHYDROUS
SITAGLIPTIN MONOPHOSPHATE MONOHYDRATE
SITAGLIPTIN PHOSPHATE
SITAGLIPTIN PHOSPHATE HYDRATE
SITAGLIPTIN PHOSPHATE MONOHYDRATE
|
|
13 |
|
Dipeptidyl-Peptidase IV Inhibitors |
|
Phase 4 |
|
|
|
14 |
|
Incretins |
|
Phase 4 |
|
|
|
15 |
|
Hormones |
|
Phase 4 |
|
|
|
16 |
|
Hormone Antagonists |
|
Phase 4 |
|
|
|
17 |
|
Neurotransmitter Agents |
|
Phase 4 |
|
|
|
18 |
|
Dopamine agonists |
|
Phase 4 |
|
|
|
19 |
|
Dopamine Agents |
|
Phase 4 |
|
|
|
20 |
|
Antiparkinson Agents |
|
Phase 4 |
|
|
|
21 |
|
Hydrocortisone succinate |
Approved |
Phase 3 |
|
2203-97-6 |
3643 |
Synonyms:
4-(2-{14,17-dihydroxy-2,15-dimethyl-5-oxotetracyclo[8.7.0.0,.0,]heptadec-6-en-14-yl}-2-oxoethoxy)-4-oxobutanoate
4-(2-{14,17-dihydroxy-2,15-dimethyl-5-oxotetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadec-6-en-14-yl}-2-oxoethoxy)-4-oxobutanoate
Cortisol 21-(hydrogen succinate)
Cortisol succinate
HYDROCORTISONE HEMISUCCINATE
|
Hydrocortisone hemisuccinate anhydrous
Hydrocortisone hydrogen succinate
HYDROCORTISONE SUCCINATE
Hydroxycortisone succinate
NSC-7576
|
|
22 |
|
Hydrocortisone acetate |
Approved, Vet_approved |
Phase 3 |
|
50-03-3 |
|
Synonyms:
21-O-acetylcortisol
BARQUINOL HC
CHLOROMYCETIN HYDROCORT
COLIFOAM
CORTEF ACETATE
CORTIFOAM
Cortisol 21-acetate
CORTRIL
CORTUCID
DRICORT
EPIFOAM
FRAMYCORT
FUCIDIN H
GENTICIN HC
GENTISONE HC
|
GPPE EAR SUSP
GPPE EYE CRM
GPPE FOAM AERO
HC45 HYDROCORT
HEMSOL-HC
HEPACORT PLUS
HYDROCAL
HYDROCORTISONE 21-ACETATE
HYDROCORTISONE ACETATE
HYDROCORTONE
LANACORT
MICORT-HC
NEO-CORTEF
NSC-741
ORABASE HCA
|
|
23 |
|
Hydrocortisone |
Approved, Vet_approved |
Phase 3 |
|
50-23-7 |
3640 5754 |
Synonyms:
(11ALPHA,14BETA)-11,17,21-TRIHYDROXYPREGN-4-ENE-3,20-DIONE
(11b)-11,17,21-Trihydroxypregn-4-ene-3,20-dione
(11beta)-11,17,21-Trihydroxypregn-4-ene-3,20-dione
(11Β)-11,17,21-trihydroxypregn-4-ene-3,20-dione
(1S,2R,10S,11S,14S,15S,17S)-14,17-DIHYDROXY-14-(2-HYDROXYACETYL)-2,15-DIMETHYLTETRACYCLO[8.7.0.0^{2,7}.0^{11,15}]HEPTADEC-6-EN-5-ONE
11 Epicortisol
11a-Hydroxycorticosterone
11alpha-Hydroxycorticosterone
11b,17,21-Trihydroxyprogesterone
11b,17a,21-Trihydroxy-4-pregnene-3,20-dione
11beta,17,21-Trihydroxyprogesterone
11beta,17alpha,21-Trihydroxy-4-pregnene-3,20-dione
11beta-Hydrocortisone
11-beta-Hydrocortisone
11beta-Hydroxycortisone
11-beta-Hydroxycortisone
11b-Hydrocortisone
11b-Hydroxycortisone
11-Epicortisol
11-Hydrocortisone
11Β,17α,21-trihydroxy-4-pregnene-3,20-dione
11Β-hydrocortisone
17a-Hydroxycorticosterone
17alpha-Hydroxycorticosterone
17-Hydroxycorticosterone
4-Pregnen-11b,17a,21-triol-3,20-dione
4-Pregnen-11beta,17alpha,21-triol-3,20-dione
4-Pregnen-11β,17α,21-triol-3,20-dione
4-Pregnene-11alpha,21-triol 3,20-dione
4-Pregnene-11b,17a,21-triol-3,20-dione
ACETASOL HC
ACTICO МИХАИЛRT
Acticort
Acticort®|Efmody®|Plenadren®
Aeroseb HC
Aeroseb-HC
Alacort
Ala-cort
Ala-scalp
Algicirtis
Alphaderm
Amberin
Anflam
Anti-inflammatory hormone
Anucort-HC
ANUGESIC HC
Anusol HC
ANUSOL PLUS HC
ANUSOL SOOTHING RELIEF
Anusol-HC
Aquacort
Aquanil HC
Balneol-HC
Barseb HC
Basan-corti
Beta-HC
b-HC
CaldeCORT spray
CALMURID HC
CANESTEN HC
Cetacort
Chronocort
CIPRO HC
Clear aid
Cleiton
Cobadex
Colocort
Compound F
CORLAN
Cor-oticin
Cortanal
Cor-tar-quin
Cort-dome
Cortef
CORTENEM
Cortenema
Cortesal
Corticreme
Cortifair
Cortifan
Cortifoam
Cortiment
Cortisol
Cortisol alcohol
Cortisolonum
Cortisporin
Cortisporin otico
Cortispray
Cortizol
Cortolotion
Cortonema
Cortoxide
Cort-quin
CORTRIL
Cremesone
Cremicort-H
Cutisol
DAKTACORT
DAKTACORT HYDROCORT
Delacort
DERMA CARE HYDROCORT
Dermacort
Derm-aid
DERMASPRAY DEMANG
Dermil
Dermolate
Dihydrocostisone
Dioderm
Dome-cort
Domolene-HC
Drotic
ECONACORT
Ef corlin
Efcorbin
Efcortelan
EFCORTELAN P
Efcortelin
Eldecort
Eldercort
Epicort
Epicortisol
Epiderm H
Esiderm H
EURAX-HC
EURAX-HYDROCORT
Evacort
EXE-CORT
Ficortril
Fiocortril
Flexicort
Foille insetti
Genacort
GERMOLOIDS HC
Glycort
GREGODERM
gyno-Cortisone
HC
|
HC #1
HC #4
HC (HYDROCORTISONE)
HC45
H-Cort
Heb cort
Heb-cort
Hi-cor
Hidalone
hidro-Colisona
Hidrocortisona
Hycort
Hycortol
Hycortole
Hydracort
Hydrasson
hydro-Adreson
hydro-Colisona
Hydrocort
HYDROCORT IN CALAMINE OILY
HYDROCORT IN CETOMACROGOL FOR A
HYDROCORT IN WTE SOFT PARAF
Hydrocortal
Hydrocorticosterone
Hydrocortisone
Hydrocortisone acetate
Hydrocortisone alcohol
Hydrocortisone base
Hydrocortisone butyrate
Hydrocortisone free alcohol
Hydrocortisone in absorbase
Hydrocortisone sodium phosphate
Hydrocortisone valerate
Hydrocortisone, (11 alpha)-isomer
Hydrocortisone, (9 beta,10 alpha,11 alpha)-isomer
Hydrocortisonum
Hydrocortistab
Hydrocortisyl
HYDROCORTONE
HYDRODERM
HYDRODERM HC
hydro-RX
Hydroskin
Hydroxycortisone
Hysone
Hytisone
Hytone
Hytone lotion
Idrocortisone
Incortin-H
Incortin-hydrogen
JUNGLE FOR
Kendall's compound F
Komed HC
Kyypakkaus
Lacticare HC
Lacticare-HC
Lactisona
Locoid
Lubricort
Maintasone
Medicort
Meusicort
Micort-HC
Mildison
MILDISON LIPOCREAM
Milliderm
neo-Cort-dome
neo-Cortef
Neosporin-H ear
Nogenic HC
NSC-10483
Nutracort
NYBADEX
Nystaform-HC
Ophthocort
Optef
Otalgine
Otic-neo-cort-dome
Otobiotic
Otocort
OTOSEPTIL
Otosone-F
OTOSPORIN
Pediotic suspension
Penecort
PERINAL
Permicort
Plenadren
Polcort H
Preparation H hydrocortisone cream
Prepcort
Prestwick_265
Prevex HC
Proctocort
PROCTOCREAM HC
Proctofoam
PROCTOFOAM HC
PROCTOSEDYL
Protocort
QUINOCORT
Racet
Rectoid
Reichstein's substance m
Remederm HC
Sanatison
Scalpicin capilar
Schericur
Scheroson F
SENTIAL HC
Sigmacort
Signef
Stie-cort
Stiefcorcil
Synacort
Systral hydrocort
Tarcortin
Terra-cortril
TERRA-CORTRIL NYSTATIN
Texacort
Timocort
TIMODINE
Topicort
TOPISONE
Transderma H
Traumaide
TRI-CICATRIN
U-cort
Uniderm
UNIROID
UNIROID HC
Vioform-hydrocortisone
VoSol HC
Vytone
XYLOPROCT
Zenoxone
β-HC
|
|
24 |
|
Ketoconazole |
Approved, Investigational |
Phase 3 |
|
65277-42-1, 142128-57-2 |
47576 3823 638701 |
Synonyms:
(+-)-cis-1-Acetyl-4-(P-((2-(2,4-dichlorophenyl)-2-(imidazol-1- ylmethyl)-1,3-dioxolan-4-yl)methoxy)phenyl)piperazine
(2S,4R)-1-Acetyl-4-(4-{[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazine
(2S,4R)-ketoconazole|COR-003|COR003|Recorlev®
1-[4-[4-[[2-(2,4-DICHLOROPHENYL)-2-(1H-IMIDAZOL-1-YLMETHYL)-1,3-DIOXOLAN-4-YL]METHOXY]PHENYL]-1-PIPERAZINYL]ETHANONE
1-ACETYL-4-(4-{[(2S,4R)-2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazine
ABBR KTC
cis-1-Acetyl-4-(4-((2-(2,4-dichlorophenyl)-2-(1H- imidazol-1-ylmethyl)-1,3-dioxolan-4-yl)methoxy)phenyl)-ketoconazol
COR003
COR-003
DAKTARIN GOLD
DAKTARIN INTENSIV
DANDRAZOL
DANDRID
EXTINA
Fungarest
Fungoral
J02AB02
Janssen brand OF ketoconazole
KETOCONAZOL
Ketoconazole
|
Ketoconazole janssen brand
KETOCONAZOLUM
Ketoderm
Ketoisdin
KETOPINE
KETOSIDIN
KETOZOLE
LEVOKETOCONAZOLE
Nizoral
NIZORAL A-D
Nizoral®|R-41400
NIZORELLE
NSC 317629
NSC-317629
Orifungal m
Panfungol
Piperazine
R-41400
SID456469
Xolegel
|
|
25 |
|
Lanreotide |
Approved |
Phase 3 |
|
108736-35-2 |
71349 6918011 |
Synonyms:
188Re-Lanreotide
2-{[(19-{[2-amino-1-hydroxy-3-(naphthalen-2-yl)propylidene]amino}-10-(4-aminobutyl)-6,9,12,15,18-pentahydroxy-16-[(4-hydroxyphenyl)methyl]-13-[(1H-indol-3-yl)methyl]-7-(propan-2-yl)-1,2-dithia-5,8,11,14,17-pentaazacycloicosa-5,8,11,14,17-pentaen-4-yl)(hydroxy)methylidene]amino}-3-hydroxybutanimidate
2-Naphthylalanyl-cyclo(cysteinyl-tyrosyl-tryptophyl-lysyl-valyl-cysteinyl)-threoninamide
BIM 23014
BIM 23014|DC 13-116|lanreotide acetate|Somatuline®
DC 13-116
Lanreotida
Lanreotide
Lanreotide acetate
Lanreotide acetic acid
Lanreotide-SR
|
L-Threoninamide, 3-(2-naphthalenyl)-D-alanyl-L-cysteinyl-L-tyrosyl-D-tryptophyl-L-lysyl-L-valyl-L-cysteinyl-, cyclic (2-7)-disulfide
Nal-cyclo(cys-tyr-TRP-lys-val-cys)THR-NH2
Nal-cyclo(cys-tyr-TRP-lys-val-cys)-THR-NH2
Naphthalenyl-cyclo(cysteinyl-tyrosyl-tryptophyl-lysyl-valyl-cysteinyl)threoninamide
Naphthyl-cyclo(cys-tyr-TRP-lys-val-cys)THR-NH2
Somatulin
Somatulina
Somatuline
SOMATULINE AUTOGEL
SOMATULINE LA
|
|
26 |
|
Hypoglycemic Agents |
|
Phase 2, Phase 3 |
|
|
|
27 |
|
Hydrocortisone 17-butyrate 21-propionate |
|
Phase 3 |
|
|
|
28 |
|
Melanocyte-Stimulating Hormones |
|
Phase 3 |
|
|
|
29 |
|
Adrenocorticotropic Hormone |
|
Phase 3 |
|
|
|
30 |
|
beta-Endorphin |
|
Phase 3 |
|
|
|
Synonyms:
|
31 |
|
glucocorticoids |
|
Phase 2, Phase 3 |
|
|
|
32 |
|
Pharmaceutical Solutions |
|
Phase 3 |
|
|
|
33 |
|
Bexarotene |
Approved, Investigational |
Phase 1, Phase 2 |
|
153559-49-0 |
82146 |
Synonyms:
3-Methyl-ttneb
4-(1-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)ethenyl)benzoic acid
4-[1-(3,5,5,8,8-PENTAMETHYLTETRALIN-2-YL)ETHENYL]BENZOIC ACID
4-[1-(5,6,7,8,-TETRAHYDRO-3,5,5,8,8-PENTAMETHYL-2-NAPHTALENYL)ETHENYL]BENZOIC ACID
BEXAROTEN
BEXAROTENE
BEXAROTÈNE
Bexaroteno
Bexarotenum
Elan brand OF bexarotene
LG100069
LG-100069
|
LG69 Compound
LGD1069
LGD-1069
LGD1069|Targretin®|Targrexin®
Ligand brand OF bexarotene
p-(1-(5,6,7,8-Tetrahydro-3,5,5,8,8-pentamethyl-2-naphthyl)vinyl)benzoate
p-(1-(5,6,7,8-Tetrahydro-3,5,5,8,8-pentamethyl-2-naphthyl)vinyl)benzoic acid
P-[1-(5,6,7,8,-TETRAHYDRO-3,5,5,8,8-PENTAMETHYL-2-NAPHTHYL)VINYL]BENZOIC ACID
Targretin
TARGRETINE
TARGRETYN
TARGREXIN
|
|
34 |
|
Gefitinib |
Approved, Investigational |
Phase 2 |
|
184475-35-2 |
123631 |
Synonyms:
4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline
GEFITINIB
Gefitinibum
Iressa
Iressa®|ZD 1839|ZD1839
Irressat
|
N-(3-Chloro-4-fluorophenyl)-7-methoxy-6-(3-(4-morpholinyl)propoxy)-4-quinazolinamide
N-(3-Chloro-4-fluorophenyl)-7-methoxy-6-(3-(4-morpholinyl)propoxy)-4-quinazolinamine
ZD 1839
ZD1839
ZD-1839
|
|
35 |
|
Benzocaine |
Approved, Investigational |
Phase 2 |
|
1994-09-7, 94-09-7 |
2337 |
Synonyms:
(P-(Ethoxycarbonyl)phenylamine
4-(Ethoxycarbonyl)aniline
4-(Ethoxycarbonyl)phenylamine
4-Aminobenzoate
4-Aminobenzoate ethyl ester
4-Aminobenzoic acid
4-Aminobenzoic acid ethyl ester
4-Carbethoxyaniline
Acetate, benzocaine
Aethoform
AEZODENT
Amben ethyl ester
Americaine
Anaesthan-syngala
Anaesthesin
Anaesthin
Anestezin
Anesthesin
Anesthesine
Anesthone
ANTHISAN PLUS
AR01
AR-01
Baby anbesol
Bensokain
Benzoak
Benzocaina
BENZOCAINE
Benzocaine acetate
Benzocaine formate
Benzocaine hydrobromide
Benzocaine hydrochloride
Benzocaine methanesulfonate
Benzocainum
BURNEZE
CHILDREN'S CHLORASEPTIC
DEQUACAINE
Dermoplast
Diet ayds
Ethoform
Ethyl 4-aminobenzoate
|
Ethyl 4-aminobenzoic acid
Ethyl aminobenzoate
Ethyl aminobenzoic acid
Ethyl P-aminobenzenecarboxylate
Ethyl p-aminobenzoate
Ethyl p-aminobenzoic acid
Ethyl p-aminophenylcarboxylate
Ethyl p-aminophenylcarboxylic acid
Ethylester kyseliny P-aminobenzoove
Formate, benzocaine
Hurricaine
Hydrobromide, benzocaine
Hydrochloride, benzocaine
Identhesin
Keloform
LANACANE
MEDILAVE
Methanesulfonate, benzocaine
NESTOSYL
Norcain
Norcaine
NSC-41531
NSC-4688
Orabase-b
Ora-jel
ORAJEL
Orthesin
p-(Ethoxycarbonyl)aniline
P-Aminobenzoate
P-Aminobenzoic acid
P-Aminobenzoic acid ethyl ester
Parathesin
Parathesine
p-Carbethoxyaniline
p-Ethoxycarboxylic aniline
Slim mint gum
Solarcaine
Solu H
Topcaine
TYROSOLVEN
TYROZETS
|
|
36 |
|
Tannic acid |
Approved |
Phase 2 |
|
1401-55-4 |
16129878 16129778 |
Synonyms:
Acid, tannic
ácido tánico
Acids, tannic
E181
FEMA NO. 3042
Gallotannic acid
|
Gallotannin
NSC-656273
TANNIC ACID
Tannic acids
Tannins
|
|
37 |
|
Prednisolone phosphate |
Approved, Vet_approved |
Phase 2 |
|
302-25-0 |
|
Synonyms:
Prednisolone 21-(dihydrogen phosphate)
Prednisolone 21-monophosphate
|
Prednisolone 21-phosphate
|
|
38 |
|
Prednisolone acetate |
Approved, Vet_approved |
Phase 2 |
|
52-21-1 |
|
Synonyms:
ECONOPRED
FLO-PRED
METICORTELONE
NSC-10966
OMNIPRED
PRED FORTE
|
PRED FTE
PRED MILD
PREDNISOLONE 21-ACETATE
PREDNISOLONE ACETATE
STERANE
ULTRACORTENOL
|
|
39 |
|
Prednisolone |
Approved, Vet_approved |
Phase 2 |
|
50-24-8 |
4894 5755 |
Synonyms:
(11b)-11,17,21-Trihydroxypregna-1,4-diene-3,20-dione
(11beta)-11,17,21-Trihydroxypregna-1,4-diene-3,20-dione
(11Β)-11,17,21-trihydroxypregna-1,4-diene-3,20-dione
1,4-Pregnadiene-11b,17a,21-triol-3,20-dione
1,4-Pregnadiene-11beta,17alpha,21-triol-3,20-dione
1,4-Pregnadiene-11β,17α,21-triol-3,20-dione
1,4-Pregnadiene-3,20-dione-11b,17a,21-triol
1,4-Pregnadiene-3,20-dione-11beta,17alpha,21-triol
1,4-Pregnadiene-3,20-dione-11β,17α,21-triol
3,20-Dioxo-11b,17a,21-trihydroxy-1,4-pregnadiene
3,20-Dioxo-11beta,17alpha,21-trihydroxy-1,4-pregnadiene
3,20-Dioxo-11β,17α,21-trihydroxy-1,4-pregnadiene
Ak-Pred
Ak-Tate
Alphadrol
Articulose-50
Codelcortone
Co-Hydeltra
Cordrol
CORTALONE
Cotogesic
Cotolone
Decaprednil
Decortin H
DEKOTIL
Delcortol
Delta F
Delta(1)-Dehydrocortisol
Delta(1)-Dehydrohydrocortisone
Delta(1)-Hydrocortisone
DELTA.1-CORTISOL
DELTA.1-Cortisol|Orapred®|Pediapred®
Delta-Cortef
Deltacortenol
DELTACORTRIL
Deltacortril Enteric
delta-dehydrocortisol
delta-dehydrohydrocortisone
delta-hydrocortisone
Deltahydrocortisone
DELTALONE
Deltasolone
Delta-Stab
Deltisilone
Depo-Medrol
Derpo Pd
DESOWEN
Dexa-Cortidelt Hostacortin H
Di adreson F
Di-Adreson F
Di-adreson-F
DiAdresonF
Dicortol
DILACORT
Donisolone
Dydeltrone
Eazolin D
Econopred
Econopred Plus
Erbacort
Erbasona
Estilsona
Fernisolone
Fernisolone P
FERNISOLONE-P
Flamasone
Hostacortin H
HYDELTRA
Hydeltrasol
HYDELTRA-TBA
Hydeltrone
Hydrodeltalone
Hydrodeltisone
Hydroretrocortin
Hydroretrocortine
IMS904
Inflamase Forte
Inflamase Mild
I-Pred
Key-Pred
Klismacort
Lentosone
Lite Pred
Medrol
|
Medrol Acetate
Metacortandralone
Methylprednisolone acetate
METICORTELONE
METI-DERM
Metreton
M-Predrol
NEO-DELTA-CORTEF
Nisolone
Nor-Pred T.B.A.
NSC-9120
NSC-9900
Ocu-Pred
Ocu-Pred Forte
Ophtho-Tate
ORAPRED
Panafcortelone
Paracortol
Paracotol
PEDIAPRED
PEVANTI
POLY-PRED
PRDL
Precortalon
Precortancyl
Precortilon
PRECORTISYL
PRECORTISYL FTE
Pred Forte
Pred Mild
Predair
Predair A
Predair Forte
Predalone 50
Predalone T.B.A.
Predate
Predate Tba
Predate-50
Predcor-25
Predcor-50
Predcor-Tba
PRED-G
Predisolone sodium phosphate
PREDL
Predne-Dome
Prednelan
Prednicen
Predni-Dome
Predniliderm
Predniretard
Prednis
Prednisolona
Prednisolona [INN-Spanish]
Prednisolone
Prednisolone acetate
Prednisolone sodium phosphate
Prednisolone tebutate
Prednisolonum
Prednisolonum [INN-Latin]
Predonin
Predonine
PRELONE
Prenolone
Rolisone
SCHERIPROCT
Scherisolon
SERVISONE
Solone
Steran
STERANE
Sterolone
Supercortisol
TRIDESILON
Ulacort
Ultra Pred
Ultracorten H
Ultracortene H
Ultracortene-H
Ultracortene-Hydrogen
VERDESO
Δ(1)-dehydrocortisol
Δ(1)-dehydrohydrocortisone
Δ(1)-hydrocortisone
Δ-cortef
|
|
40 |
|
Methylprednisolone hemisuccinate |
Approved |
Phase 2 |
|
2921-57-5 |
1875 |
Synonyms:
Methylprednisolone hemisuccinate
Methylprednisolone hemisuccinic acid
|
Methylprednisolone hydrogen succinate
Methylprednisolone succinate
|
|
41 |
|
Methylprednisolone |
Approved, Vet_approved |
Phase 2 |
|
83-43-2 |
4159 6741 |
Synonyms:
(6a,11b)-11,17,21-Trihydroxy-6-methylpregna-1,4-diene-3,20-dione
(6alpha,11beta)-11,17,21-Trihydroxy-6-methylpregna-1,4-diene-3,20-dione
(6Α,11β)-11,17,21-trihydroxy-6-methylpregna-1,4-diene-3,20-dione
1-Dehydro-6alpha-methylhydrocortisone
1-Dehydro-6a-methylhydrocortisone
1-Dehydro-6α-methylhydrocortisone
6 Methylprednisolone
6alpha-Methyl-11beta,17alpha,21-triol-1,4-pregnadiene-3,20-dione
6alpha-Methylprednisolone
6a-Methyl-11b,17a,21-triol-1,4-pregnadiene-3,20-dione
6a-Methylprednisolone
6-Methylprednisolone
6Α-methyl-11β,17α,21-triol-1,4-pregnadiene-3,20-dione
6Α-methylprednisolone
Artisone-Wyeth
Besonia
Delta(1)-6alpha-Methylhydrocortisone
delta(1)-6a-Methylhydrocortisone
Dopomedrol
Esametone
Firmacort
J3.872E
Lemod
Medesone
Medixon
Medlone 21
Medrate
Medric acid
Medrol
Medrol Adt Pak
Medrol Dosepak
Medrol®|U-67590A
Medrone
Mesopren
|
Metastab
Methyleneprednisolone
Methylprednisolon
Methylprednisolone
Methylprednisolonum
Methylprednisolonum [INN-Latin]
Metilbetasone
Metilprednisolona
Metilprednisolona [INN-Spanish]
Metilprednisolone
Metilprednisolone [Dcit]
Metipred
Metrisone
Metrocort
Metysolon
Moderin
Nirypan
Noretona
NSC-19987
Predni N Tablinen
Promacortine
Reactenol
Sieropresol
Solomet
SOLU-MEDROL
Summicort
Suprametil
U-67590A
Urbason
Urbasone
Wyacort
Δ(1)-6a-methylhydrocortisone
Δ(1)-6α-methylhydrocortisone
|
|
42 |
|
Vorinostat |
Approved, Investigational |
Phase 2 |
|
149647-78-9 |
5311 |
Synonyms:
18F Suberoylanilide hydroxamic acid
18F-SAHA
18F-Suberoylanilide hydroxamic acid
Merck brand OF vorinostat
MK0683
MK-0683
MK-0683|MK0683|SAHA|suberoylanilide hydroxamic acid|Zolinza®
N Hydroxy n' phenyloctanediamide
N1 Hydroxy N8 phenyloctanediamide
N1-Hydroxy-N8-phenyloctanediamide
NHNPODA
N-Hydroxy-n'-phenyloctanediamide
N-Hyrdroxy-n'-phenyloctanediamide
|
Octanedioate hydroxyamide phenylamide
Octanedioic acid hydroxyamide phenylamide
SAHA
SHH
Suberanilohydroxamate
Suberanilohydroxamic acid
Suberoyl anilide hydroxamic acid
Suberoylanilide hydroxamate
Suberoylanilide hydroxamic acid
VORINOSTAT
Vorinostatum
Zolinza
|
|
43 |
|
Dexmedetomidine |
Approved, Experimental, Vet_approved |
Phase 2 |
|
86347-14-0, 113775-47-6 |
68602 5311068 |
Synonyms:
(+)-4-((S)-a,2,3-Trimethylbenzyl)imidazole
(+)-4-((S)-alpha,2,3-Trimethylbenzyl)imidazole
(+)-4-((S)-Α,2,3-trimethylbenzyl)imidazole
(+-)-4-(a,2,3-Trimethylbenzyl)imidazole
(+-)-4-(alpha,2,3-Trimethylbenzyl)imidazole
(+-)-4-(Α,2,3-trimethylbenzyl)imidazole
(+)-MEDETOMIDINE
(±)-4-(α,2,3-trimethylbenzyl)imidazole
(S)-MEDETOMIDINE
Dexdor
Dexdor®|Igalmi® (dexmedetomidine sublingual film)|MPV 1440|Precedex®
DEXMEDETOMIDIN
Dexmedetomidina
DEXMEDETOMIDINE
DEXMÉDÉTOMIDINE
Dexmedetomidine hydrochloride
Dexmedetomidinum
|
Domitor
Hospira brand OF dexmedetomidine hydrochloride
Hydrochloride, dexmedetomidine
Hydrochloride, medetomidine
Levomedetomidine
Medetomidina
Medetomidina [Spanish]
Medetomidine
Medetomidine hydrochloride
Medetomidinum
Medetomidinum [Latin]
MPV 1440
MPV 785
MPV-1440
MPV-785
Precedex
|
|
44 |
|
Rosiglitazone |
Approved, Investigational |
Phase 2 |
|
122320-73-4, 155141-29-0 |
77999 |
Synonyms:
(±)-5-[p-[2-(methyl-2-pyridylamino)ethoxy]benzyl]-2,4-thiazolidinedione
(RS)-5-{4-[2-(Methyl-2-pyridylamino)ethoxy]benzyl}-2,4-thiazolidinedion
5-((4-(2-(Methyl-2-pyridinylamino)ethoxy)phenyl)methyl)-2,4-thiazolidinedione
5-((4-(2-Methyl-2-(pyridinylamino)ethoxy)phenyl)methyl)-2,4-thiazolidinedione-2-butenedioate
AVANDAMET
AVANDARYL
Avandia
Avandia®|rosiglizole
BRL-49653
BRL-49653C
BRL-49653-C
Gaudil
|
Glaxo wellcome brand OF rosiglitazone maleate
GlaxoSmithKline brand OF rosiglitazone maleate
Rosigliazone maleate
Rosiglitazon
Rosiglitazona
Rosiglitazone
Rosiglitazone maleate
Rosiglitazonum
Rosiglizole
SmithKline beecham brand OF rosiglitazone maleate
TDZ-01
|
|
45 |
|
Prednisolone hemisuccinate |
Experimental |
Phase 2 |
|
2920-86-7 |
4897 |
Synonyms:
(+)-prednisolone hemisuccinate
4-(2-{14,17-dihydroxy-2,15-dimethyl-5-oxotetracyclo[8.7.0.0,.0,]heptadeca-3,6-dien-14-yl}-2-oxoethoxy)-4-oxobutanoate
Prednisolonbisuccinat
Prednisolone 21-hemisuccinate
Prednisolone 21-succinate
|
Prednisolone bisuccinate
PREDNISOLONE HEMISUCCINATE
Prednisolone hemisuccinic acid
Prednisolone hydrogen succinate
PREDNISOLONE SUCCINATE
|
|
46 |
|
Maleic acid |
Experimental, Investigational |
Phase 2 |
|
110-16-7, 110-17-8 |
444266 444972 |
Synonyms:
(2E)-2-Butenedioate
(2E)-2-Butenedioic acid
(2E)-But-2-enedioate
(2E)-But-2-enedioic acid
(2Z)-2-Butenedioate
(2Z)-2-Butenedioic acid
(2Z)-But-2-enedioate
(2Z)-But-2-enedioic acid
(2Z)-Butene-2-dioate
(2Z)-Butene-2-dioic acid
(e)-2-Butenedioate
(e)-2-Butenedioic acid
(Z)-2-Butenedioate
(Z)-2-Butenedioic acid
(Z)-Butenedioate
(Z)-Butenedioic acid
2-(e)-Butenedioate
2-(e)-Butenedioic acid
2-Butenedioate
2-Butenedioic acid
Allomaleate
Allomaleic acid
Boletate
Boletic acid
cis-1,2-Ethylenedicarboxylate
cis-1,2-Ethylenedicarboxylic acid
cis-2-Butenedioate
cis-2-Butenedioic acid
cis-But-2-enedioate
cis-But-2-enedioic acid
cis-Butenedioate
cis-Butenedioic acid
e297
FC 33
Fumarate
Fumaric acid
Fumaricum acidum
Fumarsaeure
|
Fumarsäure
Furamag
H2Male
Hydrogen maleate
Kyselina maleinova
Lichenate
Lichenic acid
MAE
Mafusol
Maleate
MALEIC ACID
Maleic acid, ammonium salt
Maleic acid, calcium salt
Maleic acid, dipotassium salt
Maleic acid, disodium salt
Maleic acid, iron salt
Maleic acid, monoammonium salt
Maleic acid, monocopper (2+) salt
Maleic acid, monosodium salt
Maleic acid, neodymium salt
Maleic acid, potassium salt
Maleic acid, sodium salt
Maleinic acid
Malenic acid
Malezid CM
Scotchbond multipurpose etchant
Sodium maleate
Toxilate
Toxilic acid
trans-1,2-Ethylenedicarboxylate
trans-1,2-Ethylenedicarboxylic acid
trans-2-Butenedioate
trans-2-Butenedioic acid
trans-But-2-enedioate
trans-But-2-enedioic acid
trans-Butenedioate
trans-Butenedioic acid
|
|
47 |
|
Neuroprotective Agents |
|
Phase 2 |
|
|
|
48 |
|
Methylprednisolone Acetate |
|
Phase 2 |
|
|
584547 |
Synonyms:
Acetyl methylprednisolone
Acetyl-methylprednisolone
DEPMEDALONE
Depo medrol
Depo medrone
Depo-medrol
Depo-medrone
|
MEDROL ACETATE
Methylprednisolone 21 acetate
METHYLPREDNISOLONE ACETATE
Methylprednisolone acetate, (11beta,16alpha)-isomer
Methylprednisolone acetate, (11beta,16beta)-isomer
Methylprednisolone acetic acid
Methylprednisolone-21-acetate
|
|
49 |
|
Protective Agents |
|
Phase 2 |
|
|
|
50 |
|
Histone Deacetylase Inhibitors |
|
Phase 2 |
|
|
|
Interventional clinical trials:
(show top 50)
(show all 56)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
Adipokine Profile in Patients With Cushing's Disease on Pasireotide Treatment: Correlation With Disease Activity, Insulin Sensitivity and Secretion Parameters |
Completed |
NCT03080181 |
Phase 4 |
Pasireotide 0.6 MG/ML |
2 |
A Multi-center, Randomized, Open-label, Phase IV Study to Investigate the Management of Pasireotide-induced Hyperglycemia With Incretin Based Therapy or Insulin in Adult Patients With Cushing's Disease or Acromegaly |
Completed |
NCT02060383 |
Phase 4 |
Pasireotide s.c.;Sitagliptin;Liraglutide;Insulin;Pasireotide LAR;Metformin |
3 |
An Open Label, Multi-center Pasireotide Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Pasireotide Study and Are Judged by the Investigator to Benefit From Continued Pasireotide Treatment |
Active, not recruiting |
NCT01794793 |
Phase 4 |
Pasireotide;Cabergoline |
4 |
A Phase III, Multi-center, Randomized, Double-blind, 48 Week Study With an Initial 12 Week Placebo-controlled Period to Evaluate the Safety and Efficacy of Osilodrostat in Patients With Cushing's Disease |
Completed |
NCT02697734 |
Phase 3 |
osilodrostat;osilodrostat Placebo |
5 |
A Randomized, Double-blind Study to Assess the Safety and Efficacy of Different Dose Levels of Pasireotide (SOM230) Subcutaneous (sc) Over a 6 Month Treatment Period in Patients With de Novo, Persistent or Recurrent Cushing's Disease |
Completed |
NCT00434148 |
Phase 3 |
Pasireotide |
6 |
Study of Cabergoline in Treatment of Corticotroph Pituitary Tumor |
Completed |
NCT00889525 |
Phase 3 |
Cabergoline |
7 |
Phase III, Multi-center, Double-blind, Randomized Withdrawal Study of LCI699 Following a 24 Week, Single-arm, Open-label Dose Titration and Treatment Period to Evaluate the Safety and Efficacy of LCI699 for the Treatment of Patients With Cushing's Disease |
Completed |
NCT02180217 |
Phase 3 |
osilodrostat;LCI699 matching placebo |
8 |
Compassionate Use Protocol for the Administration of CORLUX® (Mifepristone) in the Treatment of the Signs and Symptoms of Endogenous Cushing's Syndrome |
Completed |
NCT01371565 |
Phase 3 |
Mifepristone |
9 |
Prevention of Metabolic Complications of Glucocorticoid Excess - a Randomised, Doubleblind,Placebo Controlled Study |
Completed |
NCT01319994 |
Phase 2, Phase 3 |
Metformin;Placebo |
10 |
A Randomized, Double-blind, Multicenter, Phase III Study to Evaluate the Efficacy and Safety of Pasireotide LAR in Patients With Cushing's Disease |
Completed |
NCT01374906 |
Phase 3 |
pasireotide LAR;SOM230 LAR 30 mg;SOM230 LAR 10 mg |
11 |
An Open-label, Multi-center, Expanded Access Study of Pasireotide s.c. in Patients With Cushing's Disease (Seascape). |
Completed |
NCT01582061 |
Phase 3 |
Pasireotide sub-cutaneous |
12 |
An Open-label Extension Study of Levoketoconazole (2S,4R-ketoconazole) in the Treatment of Endogenous Cushing's Syndrome |
Active, not recruiting |
NCT03621280 |
Phase 3 |
Levoketoconazole |
13 |
Multicenter Evaluation of the Effect of Upfront Radiosurgery on Residual Growth Hormone-secreting Pituitary Adenoma From an Endocrinological Point of View (MERGE Study): a Randomized, Phase 3 Trial |
Not yet recruiting |
NCT03439709 |
Phase 3 |
Lanreotide 60Mg Solution for Injection |
14 |
An Open-label Study of the Safety, Pharmacokinetics and Pharmacodynamics of Mifepristone in Children With Refractory Cushing's Disease |
Withdrawn |
NCT01925092 |
Phase 3 |
mifepristone |
15 |
Preoperative Bexarotene Treatment for Cushing's Disease |
Unknown status |
NCT00845351 |
Phase 1, Phase 2 |
Bexarotene |
16 |
Targeted Therapy With Gefitinib in Patients With USP8-mutated Cushing's Disease |
Unknown status |
NCT02484755 |
Phase 2 |
Gefitinib |
17 |
An Open-Label, Single Arm, Phase II Study to Evaluate the Efficacy and Safety of Pasireotide LAR on the Treatment of Patients With Clinically Non-Functioning Pituitary Adenoma |
Completed |
NCT01283542 |
Phase 2 |
Pasireotide LAR |
18 |
Extension to a Multicenter, Open-label Study to Assess the Safety and Efficacy of 600 μg SOM230, Administered Subcutaneously, Bid in Patients With Cushing's Disease |
Completed |
NCT00171951 |
Phase 2 |
Pasireotide |
19 |
Targeting Iatrogenic Cushing's Syndrome With 11β-hydroxysteroid Dehydrogenase Type 1 Inhibition (TICSI) |
Completed |
NCT03111810 |
Phase 2 |
AZD4017 and prednisolone;Placebo Oral Tablet and prednisolone |
20 |
A Multicenter, Open Label Study to Assess the Safety and Efficacy of 600 µg SOM230, Administered Subcutaneously, b.i.d. in Patients With Cushing's Disease |
Completed |
NCT00088608 |
Phase 2 |
SOM230 s.c. |
21 |
A Proof of Concept, Open-label, Forced Titration, Multi-center Study to Assess the Safety/Tolerability and Efficacy of 10-weeks Treatment of LCI699 in Patients With Cushing's Disease |
Completed |
NCT01331239 |
Phase 2 |
LCI699 |
22 |
A Phase II, Multicenter, Open-label, Non-comparative Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Tolerability of Osilodrostat in Children and Adolescent Patients With Cushing's Disease |
Recruiting |
NCT03708900 |
Phase 2 |
LCI699 |
23 |
The Effect of Vorinostat on ACTH Producing Pituitary Adenomas in Cushing's Disease |
Recruiting |
NCT04339751 |
Phase 2 |
Vorinostat |
24 |
SPI-62 as a Treatment for Adrenocorticotropic Hormone-dependent Cushing's Syndrome |
Recruiting |
NCT05307328 |
Phase 2 |
SPI-62;Placebo |
25 |
A Phase 2 Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease |
Active, not recruiting |
NCT03774446 |
Phase 2 |
Seliciclib |
26 |
Effect of Dexmedetomidine on Intraoperative Neuroendocrine Stress Response and Early Postoperative Quality of Recovery in Non-functioning Pituitary Adenoma Patients Undergoing Endoscopic Transsphenoidal Tumor Surgery |
Not yet recruiting |
NCT05005715 |
Phase 2 |
Dexmedetomidine;normal saline |
27 |
A Phase II Trial to Assess the Efficacy and Safety of Pasireotide s.c. Alone or in Combination With Cabergoline in Patients With Cushing's Disease |
Terminated |
NCT01915303 |
Phase 2 |
Pasireotide with or without cabergoline |
28 |
An Open Label, Multicenter Study Evaluating the Safety and Efficacy of Short Term (6 Weeks) Rosiglitazone Treatment in Patient's With Cushing's Disease |
Terminated |
NCT00612066 |
Phase 2 |
rosiglitazone maleate |
29 |
Treatment of Pituitary Cushing Disease With a Selective CDK Inhibitor, R-roscovitine |
Terminated |
NCT02160730 |
Phase 2 |
R-roscovitine |
30 |
Exploratory Phase 2 Study of Farletuzumab in Resectable Non-functioning Pituitary Adenoma |
Withdrawn |
NCT01203618 |
Phase 2 |
Farletuzumab |
31 |
Interdisciplinary Pituitary Disorders Centre of Excellence: Assessment of Patient Education Tools |
Unknown status |
NCT01775332 |
|
|
32 |
Prospective Observational Study of Diagnostic Yield in Cushing's Disease Using Deep Learning Based Denoising MRI |
Unknown status |
NCT04121988 |
|
|
33 |
A Pilot Study of Rosiglitazone in the Treatment of GH Secreting Pituitary Adenomas |
Unknown status |
NCT03309319 |
|
Rosiglitazone |
34 |
Etat de santé Des Patients Suivis Pour Une Maladie de Cushing Dans la région Grand-Ouest de 1990 à 2015 |
Unknown status |
NCT03297892 |
|
|
35 |
Cognitive Sequels of Cushing Syndrome |
Unknown status |
NCT02603653 |
|
|
36 |
Characteristics of Glycemic Fluctuations in Newly Diagnosed Growth Hormone-Secreting Pituitary Adenoma and Cushing Syndrome Subjects |
Completed |
NCT02574793 |
|
|
37 |
Evolution of the Metabolic, Cardiovascular, Bone Complications and of the Quality of Life in Cushing's Disease |
Completed |
NCT02568982 |
|
|
38 |
Novel Mediators of the Lipodystrophy and Metabolic Consequences of Cushing's Disease |
Completed |
NCT03817840 |
|
|
39 |
Impact of [11C]-Methionine PET/MRI in the Detection of Pituitary Adenomas Secreting ACTH and Causing Cushing's Disease |
Completed |
NCT03346954 |
|
|
40 |
National Swedish Study in Cushing´s Disease Incidence and Outcomes |
Completed |
NCT02350153 |
|
|
41 |
Cognition, Steroids, and Imaging in Cushings Disease |
Completed |
NCT00081341 |
|
|
42 |
Rhinological Outcomes in Endonasal Pituitary Surgery: A Multi-Center Observational Cohort Study |
Completed |
NCT01504399 |
|
|
43 |
The Factors Associated With the Recurrence in Patients With Cushing Disease |
Completed |
NCT02233335 |
|
|
44 |
A Prospective, Multicenter, Randomized Controlled Study of Postoperative Thrombosis Prevention in Patients With Cushing's Disease |
Recruiting |
NCT04486859 |
|
LMWH/Rivaroxaban |
45 |
Modulating the Glucose-dependent Insulinotropic Polypeptide (GIP) System in Patients With Acromegaly Due to a Pituitary Tumor |
Recruiting |
NCT03807076 |
|
|
46 |
Long-Term Follow-UP of Survivors of Pediatric Cushing Disease |
Recruiting |
NCT03831958 |
|
|
47 |
Clinical Study on Circadian Genes Dysregulation in Patients With Glucocorticoid Disorders |
Recruiting |
NCT04374721 |
|
|
48 |
Usefulness of Hair Cortisol/Cortisone Concentrations for the Monitoring of Medical Treatment in Patients With Cushing's Disease |
Recruiting |
NCT04201444 |
|
|
49 |
Non-interventional Study for the Generation of Long Term Safety and Efficacy Data of Pasireotide s.c. in Patients With Cushing's Disease (Post-Authorization Safety Study) |
Recruiting |
NCT02310269 |
|
SOM230 |
50 |
A Clinical and Genetic Investigation of Pituitary and HYPOTHALAMIC Tumors and Related Disorders |
Recruiting |
NCT00001595 |
|
|
|